0      0

JL1105EH - JL1105EH: Elranatamab,a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study

‐ Oct 20, 2023 3:00pm

Full author listing

Mohamad Mohty, MD1, Michael H. Tomasson, MD2, Bertrand Arnulf, MD3, Nizar J. Bahlis, MD4, H. Miles Prince, MD5, Ruben Niesvizky, MD6, Paula Rodrίguez-Otero, MD7, Joaquin Martinez-Lopez, MD8, Guenther Koehne, MD9, Yogesh Jethava, MD10, Afshin E. Gabayan, MD11, Don A. Stevens, MD12, Ajay K. Nooka, MD13, Noopur Raje, MD14, Shinsuke Iida, MD15, Eric Leip, PhD16, Umberto Conte, PharmD17, Akos Czibere, MD, PhD17, Andrea Viqueira, MD18, Alexander M. Lesokhin, MD19

1Sorbonne University, Hôpital Saint-Antoine, and INSERM UMRs938, Paris, France; 2Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA; 3Hôpital Saint-Louis, Paris, France; 4Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada; 5Epworth Healthcare, Melbourne, Australia; 6Weill Cornell Medical College - New York Presbyterian Hospital, New York, NY, USA; 7Clinica Universidad de Navarra, Madrid, Spain; 8Hospital Universitario 12 DE OCTUBRE, Madrid, Spain; 9Miami Cancer Institute, Miami, FL, USA; 10Indiana Blood & Marrow Transplant, Indianapolis, IN, USA; 11Beverly Hills Cancer Center, Beverly Hills, CA, USA; 12Norton Cancer Center, Louisville, KY, USA; 13Winship Cancer Institute, Atlanta, GA, USA; 14Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA; 15Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; 16Pfizer Inc, Cambridge, MA, USA; 17Pfizer Inc, New York, NY, USA; 18Pfizer SLU, Madrid, Spain; 19Division of Hematology and Oncology, Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College, New York, NY, USA.


You must be logged in and own this session in order to post comments.